Tumor-Associated CD204-Positive Macrophage Is a Prognostic Marker in Clinical Stage I Lung Adenocarcinoma
Table 3
CD204+ macrophage density in clinical stage I lung adenocarcinoma and overall survival.
Univariate analysis
Multivariate analysis
HR (95% CI)
value
HR (95% CI)
value
CD204 (high versus low)
2.37 (0.96–5.85)
0.060
0.91 (0.27–3.04)
0.879
Gender (male versus female)
7.27 (2.12–24.97)
0.002
10.31 (2.47–43.01)
0.001
Age (≥70 versus <70 years)
3.03 (1.15–7.99)
0.025
3.62 (1.28–10.22)
0.015
Side (right versus left)
0.90 (0.36–2.24)
0.825
1.05 (0.41–2.65)
0.924
Smoking (yes versus no)
1.98 (0.78–5.02)
0.152
0.33 (0.09–1.17)
0.085
Histology (LPD versus non-LPD)
1.39 (0.99–1.95)
0.058
1.11 (0.67–1.84)
0.681
Tumor stage (T1a versus T1b)
2.26 (0.92–5.57)
0.076
2.15 (0.69–6.69)
0.187
Nodal involvement (yes versus no)
6.23 (2.36–16.44)
<0.001
1.55 (0.40–6.06)
0.529
LVI (yes versus no)
7.80 (3.06–19.87)
<0.001
6.81 (1.60–29.10)
0.010
The multivariate Cox regression models initially included CD204 status, gender, age, tumor side, history of smoking, histologic subtype, tumor stage, nodal involvement, and lymphovascular invasion. Backward elimination was performed with a threshold of . DFS: disease-free survival; CI: confidence interval; HR: hazard ratio; LPD: lepidic; LVI: lymphovascular invasion.
